Imbruvica 140mg | Imbruvica 140mg capsules | Ibrutinib 140mg | Ibrutinib 140mg capsules

1
Imbruvica 140mg capsules

• Apple pharmaceuticals

2
Imbruvica 140mg capsules

•   IMBRUVICA stops a protein in B cells called
  Brutons tyrosine kinase, or BTK. BTK indicating
  is required for B cells to multiply and survive. 
•  Imbruvica 140mg may help progress abnormal B
  cells out of their nourishing environments in the
  lymph nodes, bone marrow, and other organs. 

3
INDICATION

• Mantle cell lymphoma (MCL) who have getting at
  least one prior treatment
•  Chronic lymphocytic leukaemia (CLL)/Small
  lymphocytic lymphoma (SLL)
• Marginal zone lymphoma (MZL) who getting a
  medicine by mouth or injection (systemic therapy)
  and have getting a certain type of before
  treatment

4

• Chronic graft versus host disease (cGVHD) after
  failure of 1 or more lines of systemic therapy
• Waldenström macroglobulinemia (WM)
• Chronic graft versus host disease (cGVHD) after
  failure of 1 or more lines of systemic therapy
•  Marginal zone lymphoma (MZL) who getting a
  medicine by mouth or injection 

5
ADME

• Peak plasma concentration of Imbruvica is 1-2
  hours and drug taking with food will
  increases ibrutinib exposure.
• Imbruvica has plasma protein level is 97.3 and
  Vd is 10,000L
• Ibrutinib was excretion through feces 80 and
  urine 10 Half-life of ibrutinib is 4-6 hours

6
DOSAGE

• Lymphoma 
• The recommended dose of patient is 420mg (three
  140mg capsules) per oral qday
• While in combination with bendamustine and
  rituximab the usual dose is 420mg PO qDay
  administrated q28d for up to 6 cycles until
  progression or undesirable toxicity

7

• Mantle Cell Lymphoma 
• The recommended dose of patientis 560mg (four
  140mg-mg capsules) PO qDay.
• Follow until disease progression or undesirable
  toxicity
• Marginal Zone Lymphoma  
• The recommended dose of patientis 560mg (four
  140mg-mg capsules) PO qDay.
• Follow until disease progression or undesirable
  toxicity

8

• Waldenström Macroglobulinemia
• The recommended dose of patient is 420mg (three
  140mg capsules) per oral qDay
• When combination with rituximab is 420 mg PO qDay
  plus rituximab administered weekly for 4
  consecutive weeks (weeks 1-4) 
• continued by a second course of weekly rituximab
  for 4 consecutive weeks (weeks 17-20)

9
MECHANISM

• Ibrutinib 140mg belongs to type of small-molecule
  inhibitor of BTK. Ibrutinib forms a covalent bond
  with a cysteine residue in the BTK active site,
  leading to inhibition of BTK enzymatic activity.
•  Nonclinical studies revealwhich ibrutinib
  prohibits malignant B-cell multiplication and
  survival in vivo as well as cell migration and
  substrate adhesion in vitro.

10
PRECAUTION

• Other malignancies (5-14) resulted contains
  carcinomas (1-3) the most frequent second
  primary malignancy was nonmelanoma skin cancer
  (4-11) 
• Tumor lysis syndrome intermittentlyresulted
  assess the baseline risk (eg, high tumor burden)
  and take suitable precautions 
• Based on findings in animals, can cause fetal
  risk when administered to a pregnant woman 

11
DRUG INTERACTION

• When Co administration of imbruvica 140mg with
  strong or moderate CYP3A inhibitor will
  increase ibrutinib plasma concentrations along
  with have high risk of drug related toxicity
• When Co administration of imbruvica 140mg with
  strong or moderate CYP3A inducers will
  decrease ibrutinib plasma concentrations.

12
CONTRAINDICATION

• Hypersentivity reaction
• MISSED DOSE
• If dose is missed, thereby missed dose should be
  avoid and follow the regular dosing schedule.
• Patients must consult with medical practitioner
  and follow the instructions given by them.

13
SIDE EFFECTS

• More common side effects of Imbruvica 140mg 
• Low platelets
• Musculoskeletal pain
• Swelling
• Upper respiratory tract infection
• Nausea
• Diarrhea
• Reduced neutrophils
• Decreased haemoglobin
• Fatigue
• Bruising. 

14
More common side effects of Imbruvica 140mg 

• Skin infections
• Asthenia
• Muscle spasms
• Shortness of breath
• Constipation
• Rash
• Sinusitis
• Headache
• Dehydration
• Dyspepsia
• Abdominal pain
• Vomiting
• Decreased appetite

15
CONTACT USphone No      9987711567Email   
          Info_at_myapplepharma.comWEBSITEMYAPP
LEPHARMAIBRUTINIB 140MG CAPSULES